What this study adds:
The present study shows that the differences in atomoxetine exposure (concentration dose-1 ratio) are almost 10-fold between CYP2D6 PMs and NMs, thus suggesting that the dose reduction in PMs should be substantially more than 50% as indicated by the CPIC guidelines.
CYP2C19*2 allele carriers had on average 50% higher atomoxetine serum concentrations compared to non-carriers regardless of CYP2D6 genotype.